InBio is delighted to announce that it has entered into an agreement with Merck KGaA (Darmstadt, Germany), operating as MilliporeSigma in the US and Canada, to be a global distributor of Indoor Biotechnologies’ purified food allergens. The agreement signifies the increasing importance and relevance of food allergy research and diagnostics. Please find the press release for details.

MilliporeSigma will employ its sales, marketing, and e-commerce channels and platforms to distribute InBio’s comprehensive range of natural and recombinant food allergen analytical standards. Committed to quality and backed by scientific expertise, Indoor Biotechnologies’ allergen manufacturing provides consistent and high-performance allergen products. Applications for the products include immune- and molecular diagnostics, standards and reference materials, vaccine development, and basic/applied research.

The distribution agreement covers all geographies, and products will be stocked globally to improve availability to customers. Transition of over 50 products from InBio^®’s allergen and protein portfolio to MilliporeSigma is expected to be completed in early 2021. These products will continue to be available through existing Indoor Biotechnologies channels.

Through the distribution agreement, InBio^® and MilliporeSigma can advance the shared mission of providing high quality reagents for research and diagnostics to customers worldwide. Please stay tuned for further announcements regarding the official product launch, expected to occur in the next several months.

Please contact Beattie Sturgill with any questions or comments.

InBio has completed a study comparing the allergen content of early introduction food (EIF) brands. This study demonstrated significant variability in the allergen concentration and dose in EIF from 9 manufacturers, when tested for 17 major allergens.

Join InBio scientists to discuss details of this study in an interactive webinar on Wednesday March 3^rd at 11am EST. Details of the webinar found here.